Dianthus TherapeuticsDNTH +4.58%22 Current Ratio is 29.25 as of Mar. 2026, which is 83% above its 10-year median of 15.99. GuruFocus rates DNTH with a GF Score™ of 22/100 and a GF Value™ of $2.91 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Dianthus Therapeutics ranks better than 96.24% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Dianthus Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 29.25.
Dianthus Therapeutics has a current ratio of 29.25. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Dianthus Therapeutics's Current Ratio or its related term are showing as below:
DNTH'
s Current Ratio Range Over the Past 10 Years
Min: 1.75 Med: 15.99 Max: 42.52
Current: 29.25
During the past 5 years, Dianthus Therapeutics's highest Current Ratio was 42.52. The lowest was 1.75. And the median was 15.99.
DNTH's Current Ratio is ranked better than 96.24% of 1410
companies
in the Biotechnology industry
Industry Median: 3.9
vs DNTH: 29.25
Dianthus Therapeutics (NAS:DNTH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Dianthus Therapeutics Current Ratio Related Terms
Dianthus Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Dianthus Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dianthus Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dianthus Therapeutics (DNTH) has a Current Ratio of 29.25 as of Mar. 2026. This is 83% above median its historical median of 15.99. Over the past decade, Dianthus Therapeutics' Current Ratio has ranged from 1.75 to 42.52. According to the industry distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Dianthus Therapeutics' Current Ratio too high?
Dianthus Therapeutics' current Current Ratio of 29.25 is 83% above median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 1.75 to a high of 42.52. The Biotechnology industry median Current Ratio is 3.90. Dianthus Therapeutics' value of 29.25 is 650% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' Current Ratio compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #53 out of 1410 companies for Current Ratio. This places Dianthus Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.90. Dianthus Therapeutics' value of 29.25 is 650% above this benchmark. Historically, Dianthus Therapeutics' own Current Ratio has ranged from 1.75 to 42.52 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 3.90, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current Current Ratio of 29.25 is 650% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current Current Ratio is 29.25, which is 83% above median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (DNTH) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.91, compared to a current price of $94.34 — trading 3141.9% above its estimated fair value. The current Current Ratio is 29.25, which is 83% above median its 10-year median of 15.99 and 650% above the Biotechnology industry median of 3.90. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Dianthus Therapeutics (DNTH), the current Current Ratio is 29.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (DNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of $94.34 is trading 3141.9% above its estimated GF Value™ of $2.91.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for DNTH:
Current Ratio: 29.25 (83% above median its 10-year median of 15.99)
GF Value™: $2.91 vs. price of $94.34 (3141.9% above fair value)
Industry Position: 650% above the Biotechnology median (#53 of 1410)
No single metric tells the full story. See the DNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for DNTH
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNTH has been successfully added to your 
